Global Spinal Muscular Atrophy Market Size
Market for spinal muscular atrophy is expected to reach US$ 5.6 billion by 2034, growing at a 14.8% compound annual growth rate from its 2024 valuation of US$ 1.4 billion.
A portion of the neurological system that regulates voluntary muscle movement is affected by the hereditary uncommon condition known as spinal muscular atrophy (SMA). SMA is characterized by a loss of motor neurons in the spinal cord, which weakens and impairs the action of muscles. Spinal muscular atrophy comes in four varieties, each beginning at a different age. A rare neuromuscular condition called spinal muscular atrophy (SMA) may be the cause of the gradual muscle atrophy and loss of motor neurons. It is the most frequent genetic reason for sudden infant death syndrome and is typically detected in infancy or early childhood. If neglected, it can be fatal. It will also manifest later in life and go through a milder form of the illness. A typical characteristic is the gradual weakening of voluntary muscles, including the arm, leg, and first affecting the breathing muscles. Poor head control, trouble eating, scoliosis, and joint contractures are possible associated issues. Spinal muscular atrophy is typically classified into a number of kinds based on the age at which symptoms first appear and, consequently, the severity of those symptoms. A defect (mutation) in the SMN1 gene, which codes for the protein SMN, which is essential for motor neuron survival, causes spinal muscular atrophy. Signaling between the brain and the skeletal muscles is impeded by the loss of those neurons in the medulla spinal. Another gene called SMN2 is considered a disease-modifying gene since the illness course is often milder the more copies of SMN2 there are. Based on symptoms alone, genetic testing is used to confirm the diagnosis of SMA.